The initial success of Sildenafil undeniably transformed the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a uncertain picture. Although early profits were substantial, the expiration of patents and the appearance of cheaper alternatives have eroded market share. Therefore, a thorough evaluation of p